首页 > 最新文献

Journal of liver cancer最新文献

英文 中文
A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024.
Pub Date : 2025-02-10 DOI: 10.17998/jlc.2025.02.03
Hyunjae Shin, Su Jong Yu

Many guidelines for hepatocellular carcinoma (HCC) have been published and are regularly updated worldwide. HCC management involves a broad range of treatment options and requires multidisciplinary care, resulting in significant heterogeneity in management practices across international communities. To support standardized care for HCC, we systematically appraised 13 globally recognized guidelines and expert consensus statements, including five from Asia, four from Europe, and four from the United States. These guidelines share similarities but reveal notable discrepancies in surveillance strategies, treatment allocation, and other recommendations. Geographic differences in tumor biology (e.g., prevalence of viral hepatitis, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease) and disparities in available medical resources (e.g., organ availability, healthcare infrastructure, and treatment accessibility) complicate the creation of universally applicable guidelines. Previously, significant gaps existed between Asian and Western guidelines, particularly regarding treatment strategies. However, these differences have diminished over the years. Presently, variations are often more attributable to publication dates than to regional differences. Nonetheless, Asia-Pacific experts continue to diverge from the Barcelona Clinic Liver Cancer system, particularly with respect to surgical resection and locoregional therapies, which are viewed as overly conservative in Western guidelines. Advancements in systemic therapies have prompted ongoing updates to these guidelines. Given that each set of guidelines reflects distinct regional characteristics, strengths, and limitations, fostering collaboration and mutual complementarity is essential for addressing discrepancies and advancing global HCC care.

{"title":"A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024.","authors":"Hyunjae Shin, Su Jong Yu","doi":"10.17998/jlc.2025.02.03","DOIUrl":"https://doi.org/10.17998/jlc.2025.02.03","url":null,"abstract":"<p><p>Many guidelines for hepatocellular carcinoma (HCC) have been published and are regularly updated worldwide. HCC management involves a broad range of treatment options and requires multidisciplinary care, resulting in significant heterogeneity in management practices across international communities. To support standardized care for HCC, we systematically appraised 13 globally recognized guidelines and expert consensus statements, including five from Asia, four from Europe, and four from the United States. These guidelines share similarities but reveal notable discrepancies in surveillance strategies, treatment allocation, and other recommendations. Geographic differences in tumor biology (e.g., prevalence of viral hepatitis, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease) and disparities in available medical resources (e.g., organ availability, healthcare infrastructure, and treatment accessibility) complicate the creation of universally applicable guidelines. Previously, significant gaps existed between Asian and Western guidelines, particularly regarding treatment strategies. However, these differences have diminished over the years. Presently, variations are often more attributable to publication dates than to regional differences. Nonetheless, Asia-Pacific experts continue to diverge from the Barcelona Clinic Liver Cancer system, particularly with respect to surgical resection and locoregional therapies, which are viewed as overly conservative in Western guidelines. Advancements in systemic therapies have prompted ongoing updates to these guidelines. Given that each set of guidelines reflects distinct regional characteristics, strengths, and limitations, fostering collaboration and mutual complementarity is essential for addressing discrepancies and advancing global HCC care.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microwave ablation versus liver resection for patients with hepatocellular carcinomas.
Pub Date : 2025-02-07 DOI: 10.17998/jlc.2025.02.02
Hyundam Gu, Yeonjoo Seo, Dong Jin Chung, Kwang Yeol Paik, Seung Kew Yoon, Jihye Lim

Backgrounds/aims: Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared the therapeutic outcomes of MWA with those of liver resection in real-world clinical practice.

Methods: A total of 178 patients with 259 nodules who underwent MWA or liver resection between January 2015 and July 2023 were enrolled. Local tumor progression-free survival (LTP), overall progression-free survival (OP), and overall survival (OS) were assessed based on the treatment modality for the index nodule.

Results: Of the 178 patients, 134 with 214 nodules underwent MWA, and 44 with 45 nodules underwent liver resection. The median follow-up period was 2.0 ± 1.5 years. The annual incidence of LTP was 3.7% for MWA and 1.4% for liver resection. Treatment modality did not significantly affect LTP-free survival (hazard ratio: 0.61, 95% confidence interval: 0.14-2.69, P = 0.511). For nodules larger than 3 cm, LTP-free survival was not affected by the treatment modality. Similarly, OP-free survival and OS were not influenced by treatment modality.

Conclusions: MWA and liver resection demonstrated comparable treatment outcomes in terms of local tumor control, overall recurrence, and survival. MWA may be an alternative treatment option for select patients; however, further studies are necessary to generalize these findings.

{"title":"Microwave ablation versus liver resection for patients with hepatocellular carcinomas.","authors":"Hyundam Gu, Yeonjoo Seo, Dong Jin Chung, Kwang Yeol Paik, Seung Kew Yoon, Jihye Lim","doi":"10.17998/jlc.2025.02.02","DOIUrl":"https://doi.org/10.17998/jlc.2025.02.02","url":null,"abstract":"<p><strong>Backgrounds/aims: </strong>Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared the therapeutic outcomes of MWA with those of liver resection in real-world clinical practice.</p><p><strong>Methods: </strong>A total of 178 patients with 259 nodules who underwent MWA or liver resection between January 2015 and July 2023 were enrolled. Local tumor progression-free survival (LTP), overall progression-free survival (OP), and overall survival (OS) were assessed based on the treatment modality for the index nodule.</p><p><strong>Results: </strong>Of the 178 patients, 134 with 214 nodules underwent MWA, and 44 with 45 nodules underwent liver resection. The median follow-up period was 2.0 ± 1.5 years. The annual incidence of LTP was 3.7% for MWA and 1.4% for liver resection. Treatment modality did not significantly affect LTP-free survival (hazard ratio: 0.61, 95% confidence interval: 0.14-2.69, P = 0.511). For nodules larger than 3 cm, LTP-free survival was not affected by the treatment modality. Similarly, OP-free survival and OS were not influenced by treatment modality.</p><p><strong>Conclusions: </strong>MWA and liver resection demonstrated comparable treatment outcomes in terms of local tumor control, overall recurrence, and survival. MWA may be an alternative treatment option for select patients; however, further studies are necessary to generalize these findings.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Post-Transarterial Chemoembolization: A Prospective Study Utilizing Twin Internally Cooled-Perfusion Electrodes.
Pub Date : 2025-02-07 DOI: 10.17998/jlc.2025.01.25
Sungjun Hwang, Jae Hyun Kim, Sae-Jin Park, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong Min Lee

Background: Radiofrequency ablation (RFA) is widely employed for managing recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE). However, local tumor progression (LTP) after treatment remains a significant challenge. This study evaluates the efficacy of saline-perfused bipolar RFA using twin internally cooled-perfusion (TICP) electrodes in managing recurrent HCC post-TACE.

Methods: Between September 2017 and January 2019, 100 patients with 105 nodules (mean diameter: 1.6 ± 0.5 cm) were prospectively enrolled. Bipolar RFA with TICP electrodes was performed under ultrasound-CT/MR fusion guidance. The primary outcome was the 2-year cumulative incidence of LTP.

Results: The technical success and technique efficacy rates were 100% and 97%, respectively. During a median follow-up period of 34.0 months (range: 3-41 months), the estimated LTP rates were 13.3% at 1 year and 17.7% at 2 years. Progression-free survival rates were 37.8% and 27.7% at 1 and 2 years, respectively.

Conclusions: Saline-perfused bipolar RFA using TICP electrodes demonstrates promising results for recurrent HCC after TACE, achieving high technical success and effective local tumor control rates.

{"title":"Enhanced Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Post-Transarterial Chemoembolization: A Prospective Study Utilizing Twin Internally Cooled-Perfusion Electrodes.","authors":"Sungjun Hwang, Jae Hyun Kim, Sae-Jin Park, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong Min Lee","doi":"10.17998/jlc.2025.01.25","DOIUrl":"https://doi.org/10.17998/jlc.2025.01.25","url":null,"abstract":"<p><strong>Background: </strong>Radiofrequency ablation (RFA) is widely employed for managing recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE). However, local tumor progression (LTP) after treatment remains a significant challenge. This study evaluates the efficacy of saline-perfused bipolar RFA using twin internally cooled-perfusion (TICP) electrodes in managing recurrent HCC post-TACE.</p><p><strong>Methods: </strong>Between September 2017 and January 2019, 100 patients with 105 nodules (mean diameter: 1.6 ± 0.5 cm) were prospectively enrolled. Bipolar RFA with TICP electrodes was performed under ultrasound-CT/MR fusion guidance. The primary outcome was the 2-year cumulative incidence of LTP.</p><p><strong>Results: </strong>The technical success and technique efficacy rates were 100% and 97%, respectively. During a median follow-up period of 34.0 months (range: 3-41 months), the estimated LTP rates were 13.3% at 1 year and 17.7% at 2 years. Progression-free survival rates were 37.8% and 27.7% at 1 and 2 years, respectively.</p><p><strong>Conclusions: </strong>Saline-perfused bipolar RFA using TICP electrodes demonstrates promising results for recurrent HCC after TACE, achieving high technical success and effective local tumor control rates.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma. l -精氨酸和精氨酸琥珀酸合成酶1在诱导肝癌细胞凋亡中的协同作用。
Pub Date : 2025-01-14 DOI: 10.17998/jlc.2024.12.27
Jin Sun Kim, Won-Mook Choi, Ha-Il Kim, Sung Won Chung, Jonggi Choi, Danbi Lee, Kang Mo Kim

Background/aims: Hepatocellular carcinoma (HCC) is a malignant cancer with an increasing incidence worldwide. Although numerous efforts have been made to identify effective therapies for HCC, current strategies have limitations. We present a new approach for targeting L-arginine and argininosuccinate synthetase 1 (ASS1).

Methods: ASS1 expression in HCC cell lines and primary hepatocytes was detected using PCR and western blotting. Proliferation, migration, signaling pathways, and nitric oxide production in HCC cell lines were measured using MTS, colony formation, wound healing, western blot, and Griess assays.

Results: ASS1 expression varied among the HCC cell lines, and cisplatin cytotoxicity was ASS1-dependent. L-arginine alone induced apoptosis in HCC cell lines, regardless of ASS1 expression; however, its effect was enhanced in ASS1-expressing HCC cell lines. Cisplatin cytotoxicity also increased, suggesting that L-arginine acts as a sensitizer to cisplatin in HCC cell lines. ASS1 and L-arginine produced nitric oxide and inhibited key proliferation- and survival-related signaling pathways such as PI3K/Akt and MAPK. Additionally, ASS1 and L-arginine reduced the expression of PKM1 and PKM2 in the glycolysis pathway.

Conclusions: Our study revealed that ASS1 and L-arginine exhibited anticancer effects in HCC and sensitized cisplatin-resistant HCC cells to chemotherapy. The combination of ASS1 and L-arginine significantly enhanced the anticancer effects, even in HCC cell lines with low or absent ASS1 expression. These findings highlight the critical roles of arginine and ASS1 in HCC and suggest that increasing arginine availability could be a promising therapeutic strategy.

背景/目的:肝细胞癌(HCC)是世界范围内发病率不断上升的恶性肿瘤。尽管已经做出了许多努力来确定HCC的有效治疗方法,但目前的策略有局限性。我们提出了一种靶向l -精氨酸和精氨酸琥珀酸合成酶1 (ASS1)的新方法。方法:采用PCR和western blotting检测ASS1在HCC细胞系和原代肝细胞中的表达。使用MTS、菌落形成、伤口愈合、western blot和Griess试验测量HCC细胞系的增殖、迁移、信号通路和一氧化氮产生。结果:ASS1在HCC细胞系中的表达存在差异,顺铂的细胞毒性依赖于ASS1。l -精氨酸单独诱导HCC细胞系凋亡,与ASS1表达无关;然而,其作用在表达ass1的HCC细胞系中增强。顺铂的细胞毒性也增加,提示l -精氨酸在HCC细胞系中对顺铂起增敏作用。ASS1和l-精氨酸产生一氧化氮,抑制关键的增殖和生存相关信号通路,如PI3K/Akt和MAPK。此外,ASS1和l -精氨酸降低了糖酵解途径中PKM1和PKM2的表达。结论:我们的研究表明,ASS1和l -精氨酸在HCC中具有抗癌作用,并使顺铂耐药的HCC细胞对化疗敏感。即使在ASS1低表达或不表达的HCC细胞系中,ASS1和l -精氨酸联合使用也能显著增强其抗癌作用。这些发现强调了精氨酸和ASS1在HCC中的关键作用,并表明增加精氨酸的可用性可能是一种有希望的治疗策略。
{"title":"Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma.","authors":"Jin Sun Kim, Won-Mook Choi, Ha-Il Kim, Sung Won Chung, Jonggi Choi, Danbi Lee, Kang Mo Kim","doi":"10.17998/jlc.2024.12.27","DOIUrl":"https://doi.org/10.17998/jlc.2024.12.27","url":null,"abstract":"<p><strong>Background/aims: </strong>Hepatocellular carcinoma (HCC) is a malignant cancer with an increasing incidence worldwide. Although numerous efforts have been made to identify effective therapies for HCC, current strategies have limitations. We present a new approach for targeting L-arginine and argininosuccinate synthetase 1 (ASS1).</p><p><strong>Methods: </strong>ASS1 expression in HCC cell lines and primary hepatocytes was detected using PCR and western blotting. Proliferation, migration, signaling pathways, and nitric oxide production in HCC cell lines were measured using MTS, colony formation, wound healing, western blot, and Griess assays.</p><p><strong>Results: </strong>ASS1 expression varied among the HCC cell lines, and cisplatin cytotoxicity was ASS1-dependent. L-arginine alone induced apoptosis in HCC cell lines, regardless of ASS1 expression; however, its effect was enhanced in ASS1-expressing HCC cell lines. Cisplatin cytotoxicity also increased, suggesting that L-arginine acts as a sensitizer to cisplatin in HCC cell lines. ASS1 and L-arginine produced nitric oxide and inhibited key proliferation- and survival-related signaling pathways such as PI3K/Akt and MAPK. Additionally, ASS1 and L-arginine reduced the expression of PKM1 and PKM2 in the glycolysis pathway.</p><p><strong>Conclusions: </strong>Our study revealed that ASS1 and L-arginine exhibited anticancer effects in HCC and sensitized cisplatin-resistant HCC cells to chemotherapy. The combination of ASS1 and L-arginine significantly enhanced the anticancer effects, even in HCC cell lines with low or absent ASS1 expression. These findings highlight the critical roles of arginine and ASS1 in HCC and suggest that increasing arginine availability could be a promising therapeutic strategy.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142981056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular and immune landscape of hepatocellular carcinoma for therapeutic development. 肝细胞癌治疗发展的分子和免疫景观。
Pub Date : 2024-12-06 DOI: 10.17998/jlc.2024.12.02
Hiroyuki Suzuki, Sumit Mishra, Subhojit Paul, Yujin Hoshida

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with an estimated 750,000 deaths in 2022. Recent emergence of molecular targeted agents (MTAs) and immune checkpoint inhibitors (ICIs) and their combination therapies have been transforming HCC care, but their prognostic impact in advanced-stage disease remains unsatisfactory. In addition, their application to early-stage disease is still an unmet need. Omics profiling studies have elucidated recurrent and heterogeneously present molecular aberrations involved in pro-cancer tumor (immune) microenvironment that may guide therapeutic strategies. Recurrent aberrations such somatic mutations in TERT promoter and TP53 have been regarded undruggable, but recent studies have suggested that these may serve as new classes of therapeutic targets. HCC markers such as alpha-fetoprotein (AFP), glypican-3 (GPC3), and epithelial cell adhesion molecule (EpCAM) have also been explored as therapeutic targets. These molecular features may be utilized as biomarkers to guide the application of new approaches as companion biomarkers to maximize therapeutic benefits in patients who are likely to benefit from the therapies, while minimizing unnecessary harm in patients who will not respond. The explosive number of new agents in the pipelines have posed challenges in their clinical testing. Novel clinical trial designs guided by predictive biomarkers have been proposed to enable their efficient and cost-effective evaluation. These new developments collectively facilitate clinical translation of personalized molecular-targeted therapies in HCC and substantially improve prognosis of HCC patients.

肝细胞癌(HCC)是全球癌症相关死亡的主要原因,估计2022年有75万人死亡。最近出现的分子靶向药物(mta)和免疫检查点抑制剂(ICIs)及其联合治疗已经改变了HCC的治疗,但它们对晚期疾病的预后影响仍不令人满意。此外,它们在早期疾病中的应用仍然是一个未满足的需求。组学分析研究已经阐明了与癌前肿瘤(免疫)微环境相关的复发性和异质性分子畸变,这可能指导治疗策略。复发性畸变,如TERT启动子和TP53的体细胞突变,一直被认为是无法药物治疗的,但最近的研究表明,这些可能作为新的治疗靶点。肝癌标志物如甲胎蛋白(AFP)、甘聚糖-3 (GPC3)和上皮细胞粘附分子(EpCAM)也被探索作为治疗靶点。这些分子特征可以作为生物标记物来指导新方法作为伴随生物标记物的应用,以最大限度地提高可能从治疗中受益的患者的治疗效益,同时最大限度地减少对无反应患者的不必要伤害。即将上市的新药数量激增,给它们的临床试验带来了挑战。以预测性生物标志物为指导的新型临床试验设计已被提出,以实现其高效和经济的评估。这些新进展共同促进了HCC个体化分子靶向治疗的临床转化,并大大改善了HCC患者的预后。
{"title":"Molecular and immune landscape of hepatocellular carcinoma for therapeutic development.","authors":"Hiroyuki Suzuki, Sumit Mishra, Subhojit Paul, Yujin Hoshida","doi":"10.17998/jlc.2024.12.02","DOIUrl":"https://doi.org/10.17998/jlc.2024.12.02","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with an estimated 750,000 deaths in 2022. Recent emergence of molecular targeted agents (MTAs) and immune checkpoint inhibitors (ICIs) and their combination therapies have been transforming HCC care, but their prognostic impact in advanced-stage disease remains unsatisfactory. In addition, their application to early-stage disease is still an unmet need. Omics profiling studies have elucidated recurrent and heterogeneously present molecular aberrations involved in pro-cancer tumor (immune) microenvironment that may guide therapeutic strategies. Recurrent aberrations such somatic mutations in TERT promoter and TP53 have been regarded undruggable, but recent studies have suggested that these may serve as new classes of therapeutic targets. HCC markers such as alpha-fetoprotein (AFP), glypican-3 (GPC3), and epithelial cell adhesion molecule (EpCAM) have also been explored as therapeutic targets. These molecular features may be utilized as biomarkers to guide the application of new approaches as companion biomarkers to maximize therapeutic benefits in patients who are likely to benefit from the therapies, while minimizing unnecessary harm in patients who will not respond. The explosive number of new agents in the pipelines have posed challenges in their clinical testing. Novel clinical trial designs guided by predictive biomarkers have been proposed to enable their efficient and cost-effective evaluation. These new developments collectively facilitate clinical translation of personalized molecular-targeted therapies in HCC and substantially improve prognosis of HCC patients.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea. 韩国肝细胞癌流行病学、病因学和治疗模式的发展趋势。
Pub Date : 2024-12-05 DOI: 10.17998/jlc.2024.12.04
Soo Young Hwang, Ju Dong Yang
{"title":"Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea.","authors":"Soo Young Hwang, Ju Dong Yang","doi":"10.17998/jlc.2024.12.04","DOIUrl":"https://doi.org/10.17998/jlc.2024.12.04","url":null,"abstract":"","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report. 门静脉肿瘤血栓形成肝细胞癌患者停用阿特珠单抗-贝伐单抗治疗后的持久完全应答:首次报告。
Pub Date : 2024-11-05 DOI: 10.17998/jlc.2024.09.26
Pramod Kumar, Pradeep Krishna, Rohit Maidur, Naveen Chandrashekhar, Suresh Raghavaiah

Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT.

伴有门静脉瘤栓形成(PVTT)的肝细胞癌(HCC)预后很差。根据mRECIST标准,约10%的患者可获得完全应答(CR)。治疗持续时间为疾病进展或出现不可接受的副作用之前。长期持续治疗可能会导致潜在的毒性反应和巨大的经济负担,因此尽早停止治疗是一个可行的选择。本报告介绍了三例 HCC 和 PVTT 患者在停止阿特佐-贝夫治疗后出现的持久 CR。
{"title":"Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report.","authors":"Pramod Kumar, Pradeep Krishna, Rohit Maidur, Naveen Chandrashekhar, Suresh Raghavaiah","doi":"10.17998/jlc.2024.09.26","DOIUrl":"10.17998/jlc.2024.09.26","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis. 超选择性消融化疗乙醇栓塞治疗复发性单肝细胞癌:六个月疗效分析。
Pub Date : 2024-09-01 Epub Date: 2024-05-14 DOI: 10.17998/jlc.2024.05.08
Jae Hwan Lee, Kun Yung Kim, Chong-Ho Lee, Minuk Kim, Chang Jin Yoon

Backgrounds/aims: To evaluate the safety and effectiveness of superselective ablative chemo-ethanol embolization (SACE) for the treatment of patients with recurrent single hepatocellular carcinoma (rHCC).

Methods: This retrospective study included 22 patients (19 men; median age, 63 years [range, 38-86]) with Child-Pugh class of A/ B/C (16/3/3) that underwent SACE between January and June 2023 for recurrent single HCCs measuring ≤5 cm in diameter using a mixture of 99% ethanol and ethiodized oil/doxorubicin emulsion. The primary endpoint was the 6-month tumor response, and the secondary endpoints were the 1-month tumor response and treatment-related safety. This study was approved by our institutional review board, and the requirement for informed consent was waived.

Results: SACE was successfully performed in 22 patients (95.2%). The complete response rates at 1-month and 6-month after treatment were 100.0% and 83.3%, respectively. At 6-month, local tumor progression occurred in one patient and intrahepatic distant metastasis was found in six patients (30.0%). No 6-month mortalities were reported. No adverse events greater than grade 2 or laboratory deteriorations were observed. Biliary complications or liver abscesses were not observed.

Conclusions: SACE for a single rHCC was highly effective in achieving a favorable 6-month tumor response and showed acceptable adverse events. However, further prospective studies are required to verify these findings.

背景/目的:评估超选择性消融化疗乙醇栓塞术(SACE)治疗复发性单发肝细胞癌(rHCC)患者的安全性和有效性:这项回顾性研究纳入了22名Child-Pugh分级为A/B/C(16/3/3)的患者(19名男性,中位年龄63岁[范围38-86岁]),他们在2023年1月至6月期间接受了SACE治疗,使用99%乙醇和乙碘化油/多柔比星乳剂的混合物治疗直径小于5厘米的复发性单发肝细胞癌。主要终点是 6 个月的肿瘤反应,次要终点是 1 个月的肿瘤反应和治疗相关的安全性。本研究获得了本院审查委员会的批准,并免除了知情同意的要求:22例(95.2%)患者成功实施了SACE。治疗后1个月和6个月的完全反应率分别为100%和83.3%。6个月时,1例患者出现局部肿瘤进展,6例(30%)患者出现肝内远处转移。无 6 个月死亡病例报告。未观察到超过 2 级的不良反应或实验室恶化。未发现胆道并发症或肝脓肿:SACE治疗单发rHCC疗效显著,6个月后肿瘤反应良好,不良反应可接受。然而,还需要进一步的前瞻性研究来验证这些发现。
{"title":"Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis.","authors":"Jae Hwan Lee, Kun Yung Kim, Chong-Ho Lee, Minuk Kim, Chang Jin Yoon","doi":"10.17998/jlc.2024.05.08","DOIUrl":"10.17998/jlc.2024.05.08","url":null,"abstract":"<p><strong>Backgrounds/aims: </strong>To evaluate the safety and effectiveness of superselective ablative chemo-ethanol embolization (SACE) for the treatment of patients with recurrent single hepatocellular carcinoma (rHCC).</p><p><strong>Methods: </strong>This retrospective study included 22 patients (19 men; median age, 63 years [range, 38-86]) with Child-Pugh class of A/ B/C (16/3/3) that underwent SACE between January and June 2023 for recurrent single HCCs measuring ≤5 cm in diameter using a mixture of 99% ethanol and ethiodized oil/doxorubicin emulsion. The primary endpoint was the 6-month tumor response, and the secondary endpoints were the 1-month tumor response and treatment-related safety. This study was approved by our institutional review board, and the requirement for informed consent was waived.</p><p><strong>Results: </strong>SACE was successfully performed in 22 patients (95.2%). The complete response rates at 1-month and 6-month after treatment were 100.0% and 83.3%, respectively. At 6-month, local tumor progression occurred in one patient and intrahepatic distant metastasis was found in six patients (30.0%). No 6-month mortalities were reported. No adverse events greater than grade 2 or laboratory deteriorations were observed. Biliary complications or liver abscesses were not observed.</p><p><strong>Conclusions: </strong>SACE for a single rHCC was highly effective in achieving a favorable 6-month tumor response and showed acceptable adverse events. However, further prospective studies are required to verify these findings.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment. 大量吸烟会增加肝细胞癌患者治愈后的早期死亡风险。
Pub Date : 2024-09-01 Epub Date: 2024-06-07 DOI: 10.17998/jlc.2024.06.02
Jaejun Lee, Jong Young Choi, Soon Kyu Lee

Backgrounds/aims: Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking on early mortality in HCC patients following curative treatment.

Methods: Data from the Korean Primary Liver Cancer Registry were examined for HCC patients who underwent liver resection or radiofrequency ablation between 2015 and 2018. Smoking cumulative dose was assessed in pack-years. The primary outcome was the 3-year overall survival (OS).

Results: Among 1,924 patients, 161 were classified as heavy smokers (≥40 pack-years). Heavy smokers exhibited a lower 3-year survival rate (77.1%) than nonsmokers (83.3%), with a significant difference observed in the 3-year OS (P=0.016). The assessment of smoking pack-years in relation to 3-year OS revealed a dose-dependent pattern, with the hazard ratio exceeding 1.0 at 20 pack-years and continuing to rise until 40 pack-years, reaching peak at 1.21 (95% confidence interval, 1.01-1.45). Multivariate Cox-regression analysis revealed heavy smoking, age ≥60 years, underlying cirrhosis, tumor size >3 cm, vascular invasion, and Child-Pugh class B/C as risk factors for 3-year OS. Subgroup analyses of patients with a tumor size <3 cm, absence of vascular invasion, and meeting the Milan criteria also showed inferior outcomes for heavy smokers in all three subgroups.

Conclusions: Heavy smoking, defined as a history of >40 pack-years, was linked to poorer 3-year survival outcomes in HCC patients undergoing curative treatments, underscoring the importance of smoking cessation in this population.

背景:尽管吸烟与肝细胞癌(HCC)风险增加有关,但吸烟与 HCC 死亡率的关系仍未得到充分探讨。我们的目的是评估吸烟对接受治愈性治疗的 HCC 患者早期死亡率的影响:我们研究了韩国原发性肝癌登记处在 2015 年至 2018 年间接受肝切除术或射频消融术的 HCC 患者的数据。吸烟累积剂量以包-年为单位进行评估。主要结果是3年总生存率(OS):在1924名患者中,161人被归类为重度吸烟者(≥40包年)。重度吸烟者的 3 年存活率(77.1%)低于非吸烟者(83.3%),3 年 OS 有显著差异(p = 0.016)。吸烟包年与 3 年生存率的关系评估显示出一种剂量依赖模式,在 20 包年时,危险比超过 1.0,并持续上升至 40 包年,在 1.21 时达到峰值(95% 置信区间:1.01, 1.45)。多变量 Cox 回归分析显示,重度吸烟、年龄≥ 60 岁、基础肝硬化、肿瘤大小> 3 厘米、血管侵犯和 Child-Pugh 分级 B/C 是 3 年 OS 的风险因素。对肿瘤大小小于3厘米、无血管侵犯和符合米兰标准的患者进行的亚组分析也显示,在所有三个亚组中,重度吸烟者的预后较差:重度吸烟(定义为吸烟史大于 40 包年)与接受根治性治疗的 HCC 患者较差的 3 年生存预后有关,强调了戒烟在这一人群中的重要性。
{"title":"Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment.","authors":"Jaejun Lee, Jong Young Choi, Soon Kyu Lee","doi":"10.17998/jlc.2024.06.02","DOIUrl":"10.17998/jlc.2024.06.02","url":null,"abstract":"<p><strong>Backgrounds/aims: </strong>Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking on early mortality in HCC patients following curative treatment.</p><p><strong>Methods: </strong>Data from the Korean Primary Liver Cancer Registry were examined for HCC patients who underwent liver resection or radiofrequency ablation between 2015 and 2018. Smoking cumulative dose was assessed in pack-years. The primary outcome was the 3-year overall survival (OS).</p><p><strong>Results: </strong>Among 1,924 patients, 161 were classified as heavy smokers (≥40 pack-years). Heavy smokers exhibited a lower 3-year survival rate (77.1%) than nonsmokers (83.3%), with a significant difference observed in the 3-year OS (P=0.016). The assessment of smoking pack-years in relation to 3-year OS revealed a dose-dependent pattern, with the hazard ratio exceeding 1.0 at 20 pack-years and continuing to rise until 40 pack-years, reaching peak at 1.21 (95% confidence interval, 1.01-1.45). Multivariate Cox-regression analysis revealed heavy smoking, age ≥60 years, underlying cirrhosis, tumor size >3 cm, vascular invasion, and Child-Pugh class B/C as risk factors for 3-year OS. Subgroup analyses of patients with a tumor size <3 cm, absence of vascular invasion, and meeting the Milan criteria also showed inferior outcomes for heavy smokers in all three subgroups.</p><p><strong>Conclusions: </strong>Heavy smoking, defined as a history of >40 pack-years, was linked to poorer 3-year survival outcomes in HCC patients undergoing curative treatments, underscoring the importance of smoking cessation in this population.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"253-262"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New systemic treatment options for advanced cholangiocarcinoma. 晚期胆管癌的新系统治疗方案。
Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.17998/jlc.2024.08.07
Valentina Zanuso, Giulia Tesini, Elena Valenzi, Lorenza Rimassa

Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatment. More recently, immunotherapy has changed the therapeutic landscape, as immune checkpoint inhibitors have yielded the first improvement in survival and currently, the addition of either durvalumab or pembrolizumab to standard of care cisplatin plus gemcitabine represents the new first-line treatment option. However, the use of immunotherapy in subsequent lines has not demonstrated its efficacy and therefore, it is not approved, except for pembrolizumab in the selected microsatellite instability-high population. In addition, advances in comprehensive genomic profiling have led to the identification of targetable genetic alterations, such as isocitrate dehydrogenase 1 (IDH1), fibroblast growth factor receptor 2 (FGFR2), human epidermal growth factor receptor 2 (HER2), proto-oncogene B-Raf (BRAF), neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), Kirsten rat sarcoma virus (KRAS), and mouse double minute 2 homolog (MDM2), thus favoring the development of a precision medicine approach in previously treated patients. Despite these advances, the use of molecularly driven agents is limited to a subgroup of patients. This review aims to provide an overview of the newly approved systemic therapies, the ongoing studies, and future research challenges in advanced CCA management.

胆管癌(CCA)是一种罕见的侵袭性癌症,多在晚期或转移期确诊,此时全身治疗是唯一的治疗选择。化疗一直是晚期 CCA 治疗的支柱。最近,免疫疗法改变了治疗格局,免疫检查点抑制剂(ICIs)首次改善了患者的生存率,目前,在标准疗法顺铂加吉西他滨的基础上加用 durvalumab 或 pembrolizumab 已成为新的一线治疗方案。然而,免疫疗法在后续治疗中的使用尚未证明其疗效,因此,除了在选定的微卫星不稳定性高(MSI-H)人群中使用 pembrolizumab 外,免疫疗法未获批准。此外,全面基因组剖析技术的进步已导致确定了可靶向的基因改变,如异柠檬酸脱氢酶 1 (IDH1)、成纤维细胞生长因子受体 2 (FGFR2)、人表皮生长因子受体 2 (HER2)、原癌基因 B-Raf (BRAF)、神经营养肌球蛋白受体激酶 (NTRK)、转染过程中的重排 (RET)、Kirsten 大鼠肉瘤病毒 (KRAS) 和小鼠双分化 2 同源物 (MDM2),从而促进了针对既往接受过治疗的患者的精准医疗方法的发展。尽管取得了这些进展,但分子驱动药物的使用仅限于一部分患者。本综述旨在概述新批准的系统疗法、正在进行的研究以及晚期 CCA 治疗中未来的研究挑战。
{"title":"New systemic treatment options for advanced cholangiocarcinoma.","authors":"Valentina Zanuso, Giulia Tesini, Elena Valenzi, Lorenza Rimassa","doi":"10.17998/jlc.2024.08.07","DOIUrl":"10.17998/jlc.2024.08.07","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatment. More recently, immunotherapy has changed the therapeutic landscape, as immune checkpoint inhibitors have yielded the first improvement in survival and currently, the addition of either durvalumab or pembrolizumab to standard of care cisplatin plus gemcitabine represents the new first-line treatment option. However, the use of immunotherapy in subsequent lines has not demonstrated its efficacy and therefore, it is not approved, except for pembrolizumab in the selected microsatellite instability-high population. In addition, advances in comprehensive genomic profiling have led to the identification of targetable genetic alterations, such as isocitrate dehydrogenase 1 (IDH1), fibroblast growth factor receptor 2 (FGFR2), human epidermal growth factor receptor 2 (HER2), proto-oncogene B-Raf (BRAF), neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), Kirsten rat sarcoma virus (KRAS), and mouse double minute 2 homolog (MDM2), thus favoring the development of a precision medicine approach in previously treated patients. Despite these advances, the use of molecularly driven agents is limited to a subgroup of patients. This review aims to provide an overview of the newly approved systemic therapies, the ongoing studies, and future research challenges in advanced CCA management.</p>","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"155-170"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of liver cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1